PARP Inhibitors: Narrower Labels, Wider Reach

Details werden geladen...

https://www.medscape.com/c99/p10/parp-inhibitors-2026-class-reshaped-withdrawn-approvals-and-2026a1000xd3

Teilen bei Facebook
Teilen bei Twitter
Teilen bei Pinterest
Per Mail empfehlen

PARP Inhibitors: Narrower Labels, Wider Reach

Five branded products, four tumor types, and a regulatory arc that walked back late-line ovarian approvals even as AKEEGA just reached hormone-sensitive prostate cancer.

Cancer Risk Low, Similar Across IBD Advanced Therapy Classes

https://www.medscape.com/viewarticle/cancer-risk-low-similar-across-inflammatory-bowel-disease-2026a1000x65

Login

PARP Inhibitors: Narrower Labels, Wider Reach

Ähnliche Seiten

Cancer Risk Low, Similar Across IBD Advanced Therapy Classes